To validate the CDKN2A ddPCR assay in glioma tissue samples, we investigated 66 gliomas of different types with known CDKN2A copy number status determined by NGS [20] and/or a TaqManTM copy number assay with the reference gene RPPH1, including 10 cases with homozygous CDKN2A deletion (Fig. 6b, c, Additional file 1: Table S13). This evidence concerns the gene CDKN2A and central nervous system cancer.